Turkey's oncology clinical trials market is projected to grow from $101.2 Mn in 2022 to $161.3 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the country's expanding healthcare infrastructure and increased emphasis on R&D. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Deva Holding.
Tanzania's oncology clinical trials market is projected to grow from $5.06 Mn in 2022 to $8.31 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022-30. The market will be driven by the country's high cancer burden and its rising expenditure on research and development. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Novartis International AG.
Vietnam's oncology clinical trials market is projected to grow from $63.3 Mn in 2022 to $98.8 Mn by 2030, registering a CAGR of 5.73% during the forecast period of 2022-30. The market will be driven by the big and diversified patient population available for clinical trials and a well-established clinical trial regulatory structure. The market is segmented by phase, by study design & by indication. Some of the major players include AstraZeneca PLC, Novartis AG & Hau Giang Pharmaceutical Joint Stock Company.
Thailand’s oncology clinical trials market is projected to grow from $15.2 Mn in 2022 to $23.9 Mn by 2030, registering a CAGR of 5.84% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer along with the country's strategic position and inexpensive clinical trial costs. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., FHoffmann-La Roche Ltd & Siam Bioscience Co., Ltd.
Singapore's oncology clinical trials market is projected to grow from $15.2 Mn in 2022 to $24.4 Mn by 2030, registering a CAGR of 6.1% during the forecast period of 2022-30. The market will be driven by the rising number of cancer cases and a favorable regulatory climate for clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Aslan Pharmaceuticals.
The Philippines oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $44.4 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the growing cancer burden, favorable regulatory environment, and cheaper costs. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & AstraZeneca plc.
Malaysia's oncology clinical trials market is projected to grow from $20.3 Mn in 2022 to $31.7 Mn by 2030, registering a CAGR of 5.7% during the forecast period of 2022-30. The market will be driven by the rise of oncology clinical trials in Malaysia, a well-established clinical research infrastructure, and government funding. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Biocon Malaysia.
Japan's oncology clinical trials market is projected to grow from $0.79 Bn in 2022 to $1.25 Bn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by a well-established healthcare system, advanced infrastructure, and a high prevalence of cancer. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Chugai Pharmaceutical Co., Ltd. & Ono Pharmaceutical Co., Ltd.
Egypt's oncology clinical trials market is projected to grow from $35.4 Mn in 2022 to $60.9 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by Egypt's rising cancer incidence and the government's favorable regulatory framework for clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International, EIPICO & EVA Pharma
Brazil's oncology clinical trials market is projected to grow from $316.3 Mn in 2022 to $523.4 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022-30. The market will be driven by the increased investment in healthcare and research and the rise in oncology clinical trials owing to rising cancer cases in Brazil. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Eurofarma Laboratórios S.A.
Australia's oncology clinical trials market is projected to grow from $151.8 Mn in 2022 to $260.8 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising investment in clinical research, increased patient education and engagement, and the development of new and innovative clinical trial designs. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, AstraZeneca plc & Kazia Therapeutics Limited.
The UK oncology clinical trials market is projected to grow from $328.9 Mn in 2022 to $433.1 Mn by 2030, registering a CAGR of 3.50% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the UK and efforts to promote research, collaboration, and innovation. The market is segmented by phase, study design, and indication. Some of the major players include Novartis AG, AstraZeneca & Astex Pharmaceuticals.
The UAE oncology clinical trials market is projected to grow from $63.3 Mn in 2022 to $104.7 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022-30. The market will be driven by the rising rate of cancer in the UAE and investments in developing healthcare infrastructure and research capabilities to support the field. The market is segmented by phase, study design, and indication. Some of the major players include Pfizer Inc, FHoffmann-La Roche Ltd & Julphar
Romania's oncology clinical trials market is projected to grow from $36.7 Mn in 2022 to $57.4 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022-30. The market will be driven by the country’s rising incidence of cancers and supportive regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Pfizer Inc. & Biofarm SA.
Netherlands oncology clinical trials Market is projected to grow from $32.9 Mn in 2022 to $52.4 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by the country's strong healthcare system, experienced clinical researchers, and a supportive government. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Pfizer Inc & Kiadis Pharma.
Italy's oncology clinical trials market is projected to grow from $303.6 Mn in 2022 to $448.6 Mn by 2030, registering a CAGR of 5% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in Italy & well-established research infrastructure and regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & MolMed S.p.A.
India's oncology clinical trials market is projected to grow from $230.1 Mn in 2022 to $441.8 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022-30. The market will be driven by the rising prevalence of Oncological disorders, the availability of a large patient pool with various genetic profiles, and low-cost clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd. & Cipla Ltd.
Germany's oncology clinical trials market is projected to grow from $463 Mn in 2022 to $619.2 Mn by 2030, registering a CAGR of 3.7% during the forecast period of 2022-30. The market will be driven by the strong healthcare infrastructure, focus on personalized medicine, and experienced workforce. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Bayer AG & BioNTech SE.
The France oncology clinical trials market is projected to grow from $347.9 Mn in 2022 to $494.7 Mn by 2030, registering a CAGR of 4.5% during the forecast period of 2022-30. The market will be driven by the rising prevalence of cancer cases, the modern healthcare system in the nation, and a supportive regulatory framework. The market is segmented by phase, by study design & by indication. Some of the major players include Roche Holding AG, Transgene & Ipsen.
China's oncology clinical trials market is projected to grow from $1.02 Bn in 2022 to $1.75 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the country and efforts to promote research, collaboration, and innovation. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Jiangsu Hengrui Pharmaceutical & Sino Biopharmaceutical.
The Belgium oncology clinical trials market is projected to grow from $27.8 Mn in 2022 to $42.7 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022-30. The market will be driven by increasing demand for innovative cancer therapies and a growing focus on personalized medicine. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Galapagos NV.
The Tanzania Neurology Clinical Trials market is projected to grow from $2.09 Mn in 2022 to $3.44 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022 - 2030. The market will be driven by investment in infrastructure, resources, and training for healthcare professionals, as well as collaboration between local and international stakeholders. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Sanofi S.A., AstraZeneca & GlaxoSmithKline.
The South Africa Neurology Clinical Trials market is projected to grow from $34 Mn in 2022 to $57.2 Mn by 2030, registering a CAGR of 6.73% during the forecast period of 2022 - 2030. The market will be driven by the availability of a diverse population, a large number of well-trained healthcare professionals and modern medical healthcare facilities. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Eli Lilly and Company & Biovac.
The Romania Neurology Clinical Trials market is projected to grow from $15.2 Mn in 2022 to $23.7 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022 - 2030. The market will be driven by collaborations with international research institutions and improved funding for clinical research. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Inc., Pfizer Inc. & Novartis AG.
The Poland Neurology Clinical Trials market is projected to grow from $30.3 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.95% during the forecast period of 2022 - 2030. The market will be driven by a skilled workforce, a supportive regulatory framework, and a relatively low cost of conducting research. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Inc., Pfizer Inc. & Novartis AG.